$400,000,000 is the new authorized ceiling on Tango Therapeutics' (TNGX) at-the-market equity program, disclosed in an 8-K filed with the SEC on August 11, 2026. That figure absorbs the $35,610,434 still unsold under the prior $100 million program, which the company formally terminated the same day. Net incremental authorization above the original shelf: approximately $364,389,566.
What the prior program drew
The first prospectus supplement, filed November 21, 2025 under a Sales Agreement with Leerink Partners LLC, authorized up to $100,000,000 in common stock sales. As of August 11, 2026, Tango had sold an aggregate of $64,389,566, leaving $35,610,434 unsold. The two figures sum to the $100 million headline; the math reconciles. Leerink Partners LLC, named as Sales Agent in the November 2025 agreement, carries forward as the distribution channel. Tango retains sole discretion on the timing and size of individual draws.
Structure of the expanded program
On August 11, 2026, Tango filed a new prospectus supplement under the same Sales Agreement for up to $400,000,000 in shares of common stock, par value $0.001 per share. The new ceiling is four times the original $100 million. The $35,610,434 unsold balance from the prior supplement is explicitly folded into that $400 million total. Once the new supplement was filed, the prior prospectus was terminated. The Registration Statement (Form S-3ASR, File No. 333-291684), originally filed November 21, 2025, became automatically effective upon that initial filing, so the new supplement required no separate SEC review period.
Filing details
| Item | Amount |
|---|---|
| Prior program authorized | $100,000,000 |
| Sold under prior prospectus (reported) | $64,389,566 |
| Unsold, rolled into new program | $35,610,434 |
| New program authorized | $400,000,000 |
| Net new capacity above prior ceiling | ~$364,389,566 |
Goodwin Procter LLP issued the legal opinion attached as Exhibit 5.1, with its consent included in the same exhibit. Matthew Gall, Chief Financial Officer, signed the 8-K on August 11, 2026. Tango Therapeutics is incorporated in Delaware, headquartered at 201 Brookline Ave., Suite 901, Boston, Massachusetts, and trades on the Nasdaq Global Market under the ticker TNGX.